Wave Life Sciences (WVE) Files Form 144 to Sell 217K Shares

Rhea-AI Filing Summary

Wave Life Sciences (WVE) submitted a Form 144 notice proposing the sale of 217,351 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $2,121,345.76, with an approximate sale date of 08/22/2025. The filing shows the shares were acquired as 26,495 Restricted Stock Units on 02/15/2021 and 190,856 Founders Shares on 03/31/2015. The filer reports nothing to report for securities sold in the past three months. The notice includes the standard signer representation that they are not aware of any undisclosed material adverse information.

Positive

• Form 144 filed disclosing broker, share count, aggregate value, and intended sale date
• Acquisition history provided (RSUs dated 02/15/2021 and Founders Shares dated 03/31/2015)
• No securities sold in prior three months is explicitly reported

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider resale notice of 217,351 shares valued at $2.12M; no recent sales reported.

The Form 144 documents a proposed sale rather than an executed transaction and specifies broker, class, quantity, and aggregate value. The filing identifies acquisition sources and dates—Restricted Stock Units (02/15/2021) and Founders Shares (03/31/2015)—which clarify holding origin and age. Absence of sales in the prior three months is explicitly stated. Based solely on the filing, this is a compliance disclosure for an intended covered sale under Rule 144; the filing itself contains no additional operational or financial disclosures.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure showing conformity with Rule 144 reporting for planned insider sale.

The notice provides required details: broker, intended sale date, share counts, and acquisition history. The signer affirms lack of undisclosed material adverse information and notes potential reliance on an adopted trading plan if applicable, though no 10b5-1 plan date is provided. From a governance perspective, the form serves transparency objectives; it does not, by itself, convey material corporate changes or governance actions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	217351	2121345.76	159140460	08/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/15/2021	Restricted Stock Units	Issuer			26495	02/15/2021	N/A
Common	03/31/2015	Founders Shares	Issuer			190856	03/31/2015	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Wave Life Sciences' Form 144 (WVE) report?

The Form 144 reports a proposed sale of 217,351 common shares valued at $2,121,345.76, to be sold through Morgan Stanley Smith Barney LLC on 08/22/2025.

How were the shares in the WVE Form 144 acquired?

The filing shows 26,495 shares from Restricted Stock Units acquired on 02/15/2021 and 190,856 Founders Shares acquired on 03/31/2015.

Does the filing report any securities sold by the filer in the past three months?

The Form 144 states Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed sale in the WVE Form 144?

The proposed sale is to be handled by Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.

Does the Form 144 indicate the filer knows of undisclosed material information about WVE?

By signing the notice, the filer represents they do not know any undisclosed material adverse information regarding the issuer.